Minaxolone

Chemical compound
  • none
Identifiers
  • 1-[(1S,2S,4S,5S,7S,10S,11S,14S,15S,17R)-17-(dimethylamino)-4-ethoxy-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]ethan-1-one
CAS Number
  • 62571-87-3 checkY
PubChem CID
  • 71960
IUPHAR/BPS
  • 5478
ChemSpider
  • 64967 ☒N
UNII
  • 737SKC73L0
KEGG
  • D05041 checkY
ChEMBL
  • ChEMBL2105209 ☒N
Chemical and physical dataFormulaC25H43NO3Molar mass405.623 g·mol−13D model (JSmol)
  • Interactive image
  • CCO[C@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2[C@@H](C[C@]4([C@H]3CC[C@@H]4C(=O)C)C)N(C)C)C[C@@H]1O)C
InChI
  • InChI=1S/C25H43NO3/c1-7-29-22-14-24(3)16(12-21(22)28)8-9-17-19-11-10-18(15(2)27)25(19,4)13-20(23(17)24)26(5)6/h16-23,28H,7-14H2,1-6H3/t16-,17-,18+,19-,20+,21-,22-,23+,24-,25+/m0/s1 ☒N
  • Key:NCGLTZSBTFVVAW-KNXRZYMVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Minaxolone (CCI-12923) is a neuroactive steroid which was developed as a general anesthetic but was withdrawn before registration due to toxicity seen with long-term administration in rats, and hence was never marketed.[1][2][3] It is a positive allosteric modulator of the GABAA receptor,[4] as well as, less potently, a positive allosteric modulator of the glycine receptor.[4][5]

Chemistry

See also

References

  1. ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1358–. ISBN 978-0-412-46630-4.
  2. ^ Bovill JB, Howie MC, eds. (1999). Clinical Pharmacology for Anaesthetists. W.B. Saunders. doi:10.1016/B978-0-323-03707-5.50031-0. ISBN 978-0-7020-2167-1.
  3. ^ Perouansky MA, Hemmings Jr HC (2006). "Intravenous anesthetic agents". In Hemmings HC, Hopkins PM (eds.). Foundations of Anesthesia: Basic Sciences for Clinical Practice. Elsevier Health Sciences. pp. 305–. ISBN 978-0-323-03707-5.
  4. ^ a b Lambert JJ, Harney SC, Belelli D, Peters JA (2001). "Neurosteroid modulation of recombinant and synaptic GABAA receptor". In Biggio G, Purdy RH (eds.). Neurosteroids and Brain Function. Academic Press. pp. 196–. ISBN 978-0-12-366846-2.
  5. ^ Weir CJ, Ling AT, Belelli D, Wildsmith JA, Peters JA, Lambert JJ (May 2004). "The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors". British Journal of Anaesthesia. 92 (5): 704–711. CiteSeerX 10.1.1.519.3591. doi:10.1093/bja/aeh125. PMID 15033889.
  • v
  • t
  • e
InhalationalInjection
Phenols
Barbiturates
Benzodiazepines
Opioids
Arylcyclohexylamines
Neuroactive steroids
Others
  • v
  • t
  • e
GABAA receptor positive modulators
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
  • 10-Methoxyyangonin
  • 11-Methoxyyangonin
  • 11-Hydroxyyangonin
  • Desmethoxyyangonin
  • 11-Methoxy-12-hydroxydehydrokavain
  • 7,8-Dihydroyangonin
  • Kavain
  • 5-Hydroxykavain
  • 5,6-Dihydroyangonin
  • 7,8-Dihydrokavain
  • 5,6,7,8-Tetrahydroyangonin
  • 5,6-Dehydromethysticin
  • Methysticin
  • 7,8-Dihydromethysticin
  • Yangonin
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
  • Unsorted benzodiazepine site positive modulators: α-Pinene
  • MRK-409 (MK-0343)
  • TCS-1105
  • TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators
  • v
  • t
  • e
Receptor
(ligands)
GlyRTooltip Glycine receptor
NMDARTooltip N-Methyl-D-aspartate receptor
  • See here instead.
Transporter
(blockers)
GlyT1Tooltip Glycine transporter 1
GlyT2Tooltip Glycine transporter 2
See also
Receptor/signaling modulators
GABA receptor modulators
GABAA receptor positive modulators
Ionotropic glutamate receptor modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e